1. Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review

   • Joana Magalhães
   • António Teixeira Rodrigues
   • Maria Teresa Herdeiro

   Review Article 16 October 2014 Pages: 1 - 13

   

2. Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist

   • Martine Gehin
   • Patricia N. Sidharta
   • Jasper Dingemanse

   Clinical Trial 18 October 2014 Pages: 15 - 23

   

3. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint

   • Jeroen Diepstraten
   • Esther J. H. Janssen
   • Catherijne A. J. Knibbe

   Pharmacodynamics 12 October 2014 Pages: 25 - 34

   

4. Clinical features of and genetic predisposition to drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients—investigating the relation between the HLA -B*4403 allele and lamotrigine

   • Hye Jung Park
   • Sung Ryeol Kim
   • Jae-Hyun Lee

   Pharmacogenetics 21 October 2014 Pages: 35 - 41

5. Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients

   • Li-chen Gao
   • Di Wang
   • Jie Tang

   Pharmacogenetics 23 October 2014 Pages: 43 - 50

   

6. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy

   • Sachiyo Hashi
   • Ikuko Yano
   • Kazuo Matsubara

   Pharmacogenetics 18 October 2014 Pages: 51 - 58

   

7. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes

   • Ivan Tkáč
   • Martin Javorský
   • Viera Habalová

   Pharmacogenetics 21 October 2014 Pages: 59 - 63

8. The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers

   • Peter Dogterom
   • Rik de Greef
   • Pierre A. M. Peeters

   Pharmacokinetics and Disposition 01 January 2015 Pages: 65 - 74

   

9. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

   • C. Burdet
   • O. Pajot
   • F. Mentré

   Pharmacokinetics and Disposition 21 October 2014 Pages: 75 - 83

   

10. N¹-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction

    • Fabian Müller
    • Constanza A. Pontones
    • Martin F. Fromm

    Pharmacokinetics and Disposition 22 October 2014 Pages: 85 - 94

    

11. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil

    • Jing Ling
    • Jun Shi
    • Zheng Jiao

    Pharmacokinetics and Disposition 21 October 2014 Pages: 95 - 106

    

12. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis

    • Yan Wang
    • Yamin Zou
    • Yalin Dong

    Pharmacoepidemiology and Prescription 30 October 2014 Pages: 107 - 115

    

13. Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives

    • Karin Hedenmalm
    • Arzu Gunes Granberg
    • Marja-Liisa Dahl

    Pharmacoepidemiology and Prescription 01 November 2014 Pages: 117 - 124

14. Revising the link between proton-pump inhibitors and risk of acute myocardial infarction—a case-crossover analysis

    • Aleksandra Turkiewicz
    • Raquel Perez Vicente
    • Juan Merlo

    Pharmacoepidemiology and Prescription 12 November 2014 Pages: 125 - 129